Overview

Laidlaw Capital Markets helps clients gain access to capital through the public markets. Our expertise includes specialized offerings such as:

  • IPOs
  • Follow-on and secondary offerings
  • Confidentially marketed follow-ons
  • Registered directs, and PIPEs

Investment Banking Team

James P. Ahern
James P. AhernManaging Partner, Head of Capital Markets
James Ahern serves as Managing Partner and Head of Capital Markets at Laidlaw & Company (UK) Ltd. Jim joined the firm in October of 2010 and focuses on arranging financing for both private and public companies, mainly within the healthcare vertical. In 6 years, Jim has strategically grown Laidlaw’s Capital Markets’ team and overseen the firms significant market share expansion, leading or being a part of over 2 billion dollars in transactions. Prior to Laidlaw, Mr. Ahern served as Managing Director of the Private Client Group at Aegis Capital Corp., a private investment firm. Before Aegis Capital, Mr. Ahern was a Vice President at Casimir Capital, a boutique investment bank.
Outside of the firm, Mr. Ahern is on the Board of Overseers for the Massachusetts Bay Big Brothers Big Sisters Foundation. Jim is also Vice-Chair of the BBBS Annual Golf Outing, an event which raises nearly 1 million dollars annually for the foundation. An active supporter of his Alma Mater, The Northfield Mount Hermon School, Jim serves as President of the NMH Basketball Alumni Council for Excellence.
Matt Dormer
Matt DormerManaging Director - Healthcare Investment Banking
Matt Dormer joins Laidlaw & Co. (UK) Ltd. from Summer Street Research Partners. During his time at Summer Street he completed more than 40 transactions which raised over $1.5 billion for biotechnology, medical device, and healthcare IT companies. Matt formerly worked for Wellington Management Company in the portfolio advisor group and previously worked in the equity research group covering the biotechnology sector at Fulcrum Global Partners in New York City. Prior to his experience in equity research, Matt was a scientist for a start-up biotechnology company and a research associate and teaching fellow at Harvard University, where he conducted research on tumor suppressor genes. Matt graduated from Davidson College with a BS in biology and received an MBA in finance from Northeastern University

Initial Public Offerings

Given Laidlaw Capital Markets success raising capital for companies, we have expanded our Equity Capital Markets reach to the IPO market. Our expertise at identifying emerging healthcare companies uniquely separates us from other advisors. Our team of banking, capital markets, institutional sales and research professionals are committed to acting and executing as a unified team in order to deliver compelling results for issuers.

Highlighted Transactions

Therapix
Biosciences

Initial Public Offering
Common Stock
 

$13,800,000

Sole Book Runner
March 2017

Gemphire

Initial Public Offering
Common Stock
 

$30,000,000

Co-Manager
August 2016

PhaseRx

Initial Public Offering
Common Stock
 

$18,500,000

Book Runner
May 2016

Cerecor, Inc.

Initial Public Offering
Common Stock
& Warrants

$26,000,000

Lead Manager
October 2015

Follow-On and Secondary Offerings

For existing public companies, Laidlaw Capital Markets research and distribution strength provides a valuable platform from which to lead or co-manage underwritten follow-on offerings and registered direct transactions. Our daily dialogue with healthcare focused investors provides us with a keen perspective on the capital markets and current investing climate. With a single sector focus, the Laidlaw & Company team helps corporate clients raise funds by accessing both domestic and international markets.

Highlighted Transactions

Confidentially Marketed Follow-Ons, Registered Directs, and PIPEs

Laidlaw Capital Markets has a proven track record executing confidentially marketed follow-ons, registered directs, and PIPEs. We also have experience in a wide variety of deal structures allowing us to provide our clients access to the capital markets. Through continuous innovation of our product and execution, Laidlaw Capital Markets delivers the highest quality outcome for its clients.

Highlighted Transactions

Onconova
Therapeutics

,

Confidentially Marketed Public Offering
Common Stock

$5,200,000

Sole Book Runner
April 2017

Gemphire

,

PIPE Transaction
Common Stock & Warrants
 

$12,500,000

Co-Manager
March 2017

Evoke Pharma

Confidentially Marketed
Follow-On
Common Stock

$8,050,000

Sole Book Runner
February 2017

Aeolus Pharmaceuticals

PIPE Transaction
Common Stock
& Warrants

$6,750,000

Exclusive Placement Agent
December 2015

Protea Biosciences Group, Inc


Private Placement
 

$7,415,551

Exclusive Placement Agent
March 2015

Aldeyra Therapeutics

 
PIPE Transaction
 

$7,791,560

Sole Placement Agent
January 2015

Investment Banking Advisory

Laidlaw is committed to partnering with organizations in an advisory capacity. Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets. Our team is able to help organizations strategize and navigate goals on an individual company basis. Whether one is seeking transactions such as acquisitions, divestitures, and mergers, or “going private” transactions and management-led buyouts, we have the resources, experience, and capabilities to work closely with clients to achieve the desired results.

All of our offerings

Onconova
Therapeutics

,

Confidentially Marketed Public Offering
Common Stock

$5,200,000

Sole Book Runner
April 2017

BioSig Technologies
 

,

PIPE Transaction
Common Stocks & Warrants

$4,349,954

Exclusive Placement Agent
March 2017

Therapix
Biosciences

Initial Public Offering
Common Stock
 

$13,800,000

Sole Book Runner
March 2017

Gemphire

,

PIPE Transaction
Common Stock & Warrants
 

$12,500,000

Co-Manager
March 2017

Evoke Pharma

Confidentially Marketed
Follow-On
Common Stock

$8,050,000

Sole Book Runner
February 2017

Medovex Corporation

PIPE Transaction
Common Stock & Warrants
 

$3,022,000

Exclusive Placement Agent
February 2017

Protea Biosciences Group, Inc

Convertible
Debenture
 

$1,736,000

Exclusive Placement Agent
September 2016

MabVax Therapeutics, Inc

Follow-On Offering
Common Stock
& Warrants

$9,438,750

Sole Book-Runner
August 2016

ImmunoCellular

Follow-On Offering
Common Stocks
& Warrants

$7,400,000

Lead Manager
August 2016

Gemphire

Initial Public Offering
Common Stock
 

$30,000,000

Co-Manager
August 2016

PhaseRx

Initial Public Offering
Common Stock
 

$18,500,000

Book Runner
May 2016

Medovex Corporation

PIPE Transaction
Common Stock
& Warrants

$1,398,033

Placement Agent
April 2016

Regenmed Therapeutics


Sale of Company
 

Undisclosed Amount

Financial Advisory
March 2016

Aeolus Pharmaceuticals

PIPE Transaction
Common Stock
& Warrants

$6,750,000

Exclusive Placement Agent
December 2015

Cerecor, Inc.

Initial Public Offering
Common Stock
& Warrants

$26,000,000

Lead Manager
October 2015

ContraVir Pharmaceuticals

Follow-On Offering
Common Stock
& Warrants

$15,000,000

Sole Book-Runner
October 2015

MabVax Therapeutics, Inc

Follow-On Offering
Common Stock
& Warrants

$2,750,000

Sole Book-Runner
October 2015

Sevion Therapeutics

PIPE Transaction
Common Stocks
& Warrants

$7,325,217

Exclusive Placement Agent
July 2015

Actinium Pharmaceuticals


Registered Direct
 

$5,000,000

Exclusive Placement Agent
June 2015

Aldeyra Therapeutics

Follow-On Offering
Common Stock
 

$20,250,000

Co-Manager
May 2015

Viking Therapeutics

Initial Public Offering
Common Stock
 

$27,600,000

Sole Book-Runner
May 2015

BioSig Technologies


PIPE Transaction
 

$4,009,000

Exclusive Placement Agent
April 2015

Protea Biosciences Group, Inc


Private Placement
 

$7,415,551

Exclusive Placement Agent
March 2015

MabVax Therapeutics, Inc

Private Placement
 

$11,600,000

Financial Advisor
March 2015

ADMA Biologics

Follow-On Offering
Common Stock
 

$9,800,000

Co-Manager
March 2015

Actinium Pharmaceuticals

Follow-On Offering
Common Stock
& Warrants

$20,000,000

Sole Book-Runner
February 2015

Aldeyra Therapeutics

 
PIPE Transaction
 

$7,791,560

Sole Placement Agent
January 2015

Medovex Corporation

Initial Public Offering
Common Stock
& Warrants

$9,200,000

Sole Book-Runner
December 2014

Mast Therapeutics, Inc.

Follow-On Offering
Common Stock
& Warrants

$21,000,000

Co-Manager
November 2014

Relmada Therapeutics

 
Warrant Exercise
 

$15,254,362

Exclusive Placement Agent
October 2014

Cel-Sci Corporation

Follow-On Offering
Common Stock
& Warrants

$7,000,000

Sole Book-Runner
October 2014

Actinium Pharmaceuticals

 
Follow-On Offering
 

$12,525,000

Lead Manager
June 2014

Relmada Therapeutics

 
Common Stock & Warrants
 

$28,000,000

Exclusive Placement Agent
June 2014

Cel-Sci Corporation

Follow-On Offering
Common Stock
& Warrants

$10,000,000

Joint Book-Runner
April 2014

Cyclacel Pharmaceuticals

Follow-On Offering
Common Stock
 

$10,000,000

Sole Book-Runner
April 2014

NovaBay Pharmaceuticals

Follow-On Offering
Common Stock
& Warrants

$6,720,000

Sole Book-Runner
March 2014

Actinium Pharmaceuticals

 
Common Stock & Warrants
 

$6,363,720

Placement Agent
January 2014

Protea Biosciences Group, Inc

 
Common Stock & Warrants
 

$7,762,320

Placement Agent
December 2013

Cel-Sci Corporation

Follow-On offering
Common Stock & Warrants
 

$3,000,000

Sole Book-runner
December 2013

ADMA Biologics

Initial Public Offering
Common Stock
 

$28,347,500

Co-Manager
October 2013

Cel-Sci Corporation

Follow-On Offering
Common Stock
& Warrants

$17,826,087

Co-Manager
October 2013

Relmada Therapeutics

Convertible
Preferred Stock
& Warrants

$8,000,000

Placement Agent
September 2013

Boston Therapeutics

 
Common Stock & Warrants
 

$5,297,698

Placement Agent
September 2013

Relmada Therapeutics

Convertible Bridge
Notes & Warrants
 

$750,000

Placement Agent
September 2013

Alliqua

Common Stock &
Warrants
 

$3,000,000

Co-Manager
July 2013

BioSig Technologies

Convertible
Preferred Stock
 

$2,800,000

Exclusive Placement Agent
July 2013

Actinium Pharmaceuticals, Inc.

Common Stock &
Warrants
 

$5,151,450

Placement Agent
December 2012